2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.

Size: px
Start display at page:

Download "2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules."

Transcription

1 Slide New Data Items Data Due in: Days In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.

2 Slide 2 5 New Data Items Ambiguous Terminology Date of Conclusive Terminology Multiplicity Counter Date of Multiple Tumors Type of Multiple Tumors Reported as One Primary 2 To help document and describe some of the situations that result from the new rules, for example two breast tumors abstracted as a single primary, it was determined it would be best to do this with a few new data items. There are five new data items. There are 3 new data items used directly with the Multiple Primary Rules to help describe when there was more than one tumor abstracted as a single primary. These data items are: Multiplicity Counter Date of Multiple Tumors (plus the Flag field) Type of Multiple Tumors Reported as One Primary The other two new data items are not part of the multiple primary rules but were introduced at the same time. They have more to do with the basis of how the tumor was diagnosed. These data items are: Ambiguous Terminology Date of Conclusive Terminology (plus the Flag field)

3 Slide 3 Rational for new data items Identify cases in which the diagnosis was based on ambiguous terminology. Prostate: probably adenocarcinoma Prostate: Adenocarcinoma Identify cases in which there was more than one tumor abstracted as a single primary. 3 When there is a statement of diagnosis, physicians may use terms to describe how conclusive they feel the diagnosis is. These terms are considered to be ambiguous and include terms such as probable, possible, suspects, and suggests. The terms probable and suspects are ambiguous terms that DO constitute a diagnosis, probably adenocarcinoma, for example. The terms possible and suggests are ambiguous terms that DO NOT constitute a diagnosis. Other times, ambiguous terms are not used at all. There is just a strict statement of cancer, prostate adenocarcinoma, for example. These data items help let the user of the data know if the diagnosis was based on ambiguous or conclusive terminology. This information is helpful when considering whether to include a case in special studies or to contact patients for follow-up. If there are two or more tumors, the physician may say this is a multiple primary, especially if only one of the tumors was biopsied. However, when you apply this case to the rules, the instructions state this would be one primary. The word primary is used in two different ways. Physicians don t always mean a new primary the way a cancer registrar uses the term. A new primary to the registrar means de novo, or one is not a metastasis from another tumor. The tumors started growing independently of each other. When we talk about a new primary we are using it in the epidemiological sense. If there are two infiltrating duct primaries there are two de novo tumors. Even though these did start growing independent of each other, the epidemiological interpretation says these should be coded as a single primary. The new multiplicity data item would identify this as a single primary, but with two separate tumors. The benefit of this data item is that this information is still available to the physician and for studies.

4 Slide 4 New Data Items Code only for cases diagnosed on or after 1/1/2007 What if the date of diagnosis is before 1/1/2007? Leave these 5 data items blank 4 These data items are only collected for cases diagnosed on or after January 1, For cases diagnosed prior to 2007, these data items should be left blank. Your software vendor may instruct you to handle these differently. If so, that s ok. But, as a general instruction, these should be left blank. There is no benefit in collecting them because they were not collected consistently for all cases diagnosed prior to 2007.

5 Slide 5 Ambiguous Terminology Identifies all cases accessioned based on ambiguous terminology. Includes: Death Clearance only Autopsy only Allows identification of cases in database Cases excluded from research studies Direct patient contact not recommended 5 Page 335 The coding instructions for these data items begin on page 335 of the MPH Coding Rules Manual. It is recommended that you follow along in your manual as we discuss these data items. The first data item we will discuss is the Ambiguous Terminology data item. This data item identifies all cases, including Death Clearance only (in central registries) and autopsy only cases, that were accessioned based on ambiguous terminology.

6 Slide 6 Ambiguous Terminology Ambiguous Terms Reportable case when an ambiguous term is used as basis for a diagnosis Only use terms listed on page 337 Conclusive Terms A clear and definite statement of cancer Statement may be from: Physician (clinical diagnosis) Laboratory test Autopsy, cytologic findings, and/or pathology 6 This data items looks at two elements. Was the diagnosis made using ambiguous terms or conclusive terms? And, if it was an ambiguous term, at any time later did they confirm the diagnosis with a conclusive term? Only the ambiguous terms provided with this data item are to be used to say that the basis for the diagnosis used ambiguous terminology. These terms are listed on page 337.

7 Slide 7 Ambiguous Terms that are Reportable Apparent(ly) Appears* Comparable with* Compatible with* Consistent with Favor(s) Malignant appearing* Most likely Presumed Probable Suspect(ed) Suspicious (for) Typical (of) * Effective with cases diagnosed 1/1/1998 and later 7 Listed here are the valid terms. Notice that consistent with is considered ambiguous terminology for assigning this data item.

8 Slide 8 Code Label Definition Time Frame 0 Conclusive term There was a conclusive diagnosis within 60 days of the original diagnosis. Case was accessioned based on conclusive terminology. Includes all diagnostic methods such as clinical diagnosis, cytology, pathology, etc. 1 Ambiguous term only The case was accessioned based only on ambiguous terminology. There was no conclusive terminology during the first 60 days following the initial diagnosis. Includes all diagnostic methods except cytology. Note: Cytology is excluded because registrars are not required to collect cases with ambiguous terms describing a cytology diagnosis. Within 60 days of the date of initial diagnosis. N/A 8 Use Code 0 when a case is accessioned based on conclusive terminology. The diagnosis had clear and definite terminology describing the malignancy within two months of the original diagnosis. Note: Usually the patient undergoes a diagnostic work-up because there is a suspicion of cancer (ambiguous terminology). For example, a mammogram may show calcifications suspicious for carcinoma. The date of the mammogram is still the date of initial diagnosis. When there is a clear and definite diagnosis within two months of that mammogram (date of initial diagnosis) such as the pathology from an excisional biopsy showing intraductal carcinoma, assign a code 0. Examples of a conclusive diagnosis: 1. Adenocarcinoma in TURP chips. 2. Mammogram suspicious for DCIS. Excisional biopsy 1 week later positive for DCIS. Use Code 1 when a case is accessioned based on ambiguous terminology and there is no clear and definite terminology used to describe the malignancy within 60 days of the date of initial diagnosis. The diagnosis may be from a pathology report, a radiology report, an imaging report, or on the medical record. Examples of an ambiguous diagnosis: 1. Chest MRI shows a malignant appearing lesion in the right upper lobe. Patient refused further workup or treatment. 2. Pt with elevated PSA admitted for TRUS Biopsy. Pathology: Prostatic chips consistent with adenocarcinoma. No further information is available.

9 Slide 9 Code Label Definition Time Frame 2 Ambiguous term followed by conclusive term 9 Unknown term The case was originally assigned a code 1 (was accessioned based only on ambiguous terminology). More than 60 days after the initial diagnosis the information is being updated to show that a conclusive diagnosis was made by any diagnostic method including clinical diagnosis, cytology, pathology, autopsy, etc. There is no information about ambiguous terminology. 60 days or more after the date of diagnosis N/A 9 Use Code 2 when a case was originally accessioned based on ambiguous terminology, but was then followed by clear and definite terminology more than 60 days after the initial diagnosis. For example, follow-back to a physician or in a subsequent readmission (following the initial 60 day period) may eventually confirm the cancer using a conclusive cancer term. If so, change the code of 1 to a Code 2. Examples: A biopsy of the thyroid reads: most likely thyroid cancer. Three months later a biopsy is positive for papillary follicular cancer. The case would have been coded 1 Ambiguous term only when originally abstracted because of the use of the ambiguous terminology most likely. The code should be changed 2 - Ambiguous term followed by conclusive term.

10 Slide 10 Date of Conclusive Terminology Date of definite statement of malignancy Abstractor must enter the valid date that the malignancy was described conclusively May have to change the code in the Ambiguous Terminology field from 1 to 2 10 Page 338 The next data item is the Date of Conclusive Terminology. This data items describes the date that a definite statement of malignancy was made. This will only apply when the Ambiguous Terminology was originally a code 1 but then changed to a code 2 when conclusive terminology was used more than 60 days after the date of diagnosis. These data items are followed and updated over time and will be something that you will have to remember to look for and update if appropriate.

11 Slide 11 Date and Date Flag Fields Read pages 7-8 in the FORDS (Coding Dates) See next slide for special codes that can be used in this course. Flag fields will not be included in the exercises in this lesson. 11 Begin by reading the section on Coding Dates in the FORDS, pages 7-8. Beginning with the FORDS 2010 (implemented with cases diagnosed 1/1/2010 and after), the format for transmitting dates in the abstract were revised. Prior to FORDS 2010, special codes were used in the date fields if treatment was not given ( ), the date was unknown (code ) or if the treatment was recommended but unknown if given (code ). Now, only valid dates can be transmitted in the date fields and the Flag fields are used to describe these other situations. The FORDS says that the "Interoperable" format will be used for TRANSMITTING data. For example, when the data is sent from the hospital registry to the NCDB. Each cancer registry software vendor will determine how the date is to be ENTERED. If the date is entered in the traditional format, the software computer programs will convert the format to the interoperable format for the transmission of data. Because there may be a choice of how the date is to be entered when using actual cancer registry software systems, it is important to learn what format must be used at the particular facility in which you work. IMPORTANT INSTRUCTIONS FROM THE INSTRUCTOR: Using the Flag fields will be discussed in more detail in the Oncology Treatment and Coding course. The FORDS does not specify a specific format to be used for the date fields, but rather states that the cancer registry software providers will provide the instructions for the format to be used. For the purposes of this course and the CRM program, all dates will use the TRADITIONAL format (MMDDYYYY). When completing exercises and answering quiz questions, use the traditional format. If any part of the date information is unknown, it should be filled in with 9's ( if the entire date is unknown, if only the year is known, if only the month and year are known, etc.) for unknown if an estimated date cannot be determined. If the date does not apply, such as that particular type of treatment was not given, then the date field is filled in 0's ( ). The Flag field will not be collected in lesson as detailed instructions for the flag fields will not be discussed until the Oncology Treatment and Coding course. If you are working in a cancer registry, you should check with your software provider to determine the appropriate format to be used for data entry in your cancer registry software system.

12 Slide 12 Special (Date) Codes MMDDCCYY format 99 for unknown month or day 9999 for unknown year Accessioned based on ambiguous terminology only Code 1 in data item Ambiguous Terminology Not applicable Case was accessioned based on conclusive diagnosis Code 0 in data item Ambiguous Terminology Unknown date Unknown if diagnosis was based on ambiguous terminology or conclusive terminology Code 9 in data item Ambiguous Terminology 12 If the Ambiguous Terminology data item was not updated to conclusive terminology, there are three special codes that should be used. Enter if the case was accessioned based on ambiguous terminology only. There has to be a Code 1 in the data item Ambiguous Terminology. Enter if the is not applicable. This will be the case when the case was accessioned based on conclusive diagnosis and there is a Code 0 in data item Ambiguous Terminology. Enter when the date is unknown date. Also use is it is unknown if the diagnosis was based on ambiguous terminology or conclusive terminology. There has to be a Code 9 in data item Ambiguous Terminology. As with any date, coding unknown should be avoided. Assign an estimated date if possible.

13 Slide 13 Multiplicity Counter Identifies cases with multiple tumors reported as a single primary Do not count metastatic tumors Do not count foci when single or multiple foci present If tumor is multifocal and the foci are measured, then count them Use multiple primary rules to determine if single primary or multiple primaries 13 Page 339 The next three data items we discuss work directly with the MPH rules. The first data item is Multiplicity Counter. This data item counts the number of tumors (or multiplicity) reported as a single primary. For this data item, do not count tumors specifically stated to be metastatic. When there is a tumor or tumors with separate single or multiple foci, ignore/do not count the foci When the tumor is multifocal or multicentric and the foci of tumor are measured, count them as tumors When the tumor is multifocal or multicentric and the foci of tumor are not measured, code as 99 Now, you should have already used the multiple primary rules to determine if you have a single primary or multiple primaries before you get to this point of coding these data items. So, this data item is referring to those cases in which there multiple tumors and the rules determined that it is one primary.

14 Slide 14 Multiplicity Counter - Codes 01 One tumor only 02 Two tumors present 03 Three tumors present : 88 Information on multiple tumors not collected/not applicable for this site 99 Multiple tumors present, unknown how many 14 And, here are some examples of the codes that you will use. Use code 01 when: There is a single tumor in the primary site being abstracted There is a single tumor with separate unmeasured foci of tumor Use code 02 when there were two tumors present and the rules said to abstract as a single primary. Use code 03 when there are three tumors present, and so on. Code 88 is used when information on multiple tumors is not collected or is not applicable for that primary site. This includes: Leukemia Lymphoma Immunoproliferative disease Unknown primary Use code 99 when you know there are multiple tumors present, but the exact number is unknown. This includes situations when: The original pathology report is not available and the documentation does not specify whether there was a single or multiple tumors in the primary site. The tumor is described as diffuse. The operative or pathology report describes multiple tumors but does not give an exact number. It is unknown if there is a single tumor or multiple tumors and the multiple primary rules instructed you to default to a single tumor.

15 Slide 15 Date of Multiple Tumors Identifies the date patient diagnosed with multiple tumors Use multiple primary rules to determine if single primary or multiple primaries May or may not be the same date as date of diagnosis Only when multiple tumors are present at diagnosis Change Multiplicity Counter to 02 and enter the date the second tumor was diagnosed when subsequent tumor(s) are counted as same primary 15 Page 341 The next data item identifies the month, day and year the patient was diagnosed with multiple tumors that were reported as a single primary. Again, you would have already used the multiple primary rules to determine if it is a single primary or a multiple primary. The date the patient was diagnosed with multiple tumors may or may not be the same as the date of diagnosis. Obviously, if there were multiple tumors present at diagnosis, then this date will be the same as the date of diagnosis. Don t forget: You will also need to remember to change the Multiplicity Counter data item from code 01 to code 02 and enter the date the second tumor was diagnosed if the subsequent tumor(s) are considered as same primary according to the MPH rules.

16 Slide 16 Special (Date) Codes MMDDCCYY format 99 for unknown month or day 9999 for unknown year Single tumor Information on multiple tumors not collected/not applicable for this site Unknown date 16 Although coding 9 s for any part of a date that is unknown is allowed, it is recommended that you investigate further prior to coding unknown. If possible, estimating a date is preferred to coding unknown. Assign when there is only a single tumor. Assign when information on multiple tumors is not collected or is not applicable for this site. Assign if the date of multiple tumors is unknown.

17 Slide 17 Type of Multiple Tumors Reported as one Primary Identifies the type(s) of multiple tumors abstracted as a single primary Example: both in situ, both invasive, one in situ and the other invasive, etc. Do not count metastatic tumors 17 Page 342 The last data item identifies the type of multiple tumors abstracted as a single primary. That is, were the tumors all invasive, all in situ, or both. Again, we are not looking at tumors stated to be metastatic.

18 Slide 18 Code Code Text Description 00 Single tumor All single tumors. Includes single tumors with both in situ and invasive components. 10 Multiple benign 11 Multiple borderline At least two benign tumors in same organ/primary site Use this code for reportable tumors in intracranial and CNS sites only. At least two borderline tumors in same organ/primary site Use this code for reportable tumors in intracranial and CNS sites only 12 Benign and borderline 20 Multiple in situ At least one benign AND at least one borderline tumors in same organ/ primary site Use this code for reportable tumors in intracranial and CNS sites only At least two in situ tumors in the same organ/primary site 18 There are quite a few choices for describing the types of tumors abstracted as a single primary. First of all, if there was just a single tumor, it is always 00. It doesn t matter if it was all in situ, all invasive, or both. Codes apply when there is more than one tumor abstracted as a single primary. Codes in the 10 range are for benign and borderline tumors. These codes will only be used when there is a reportable non-malignant CNS tumor. Unless, your facility requires you to collect other benign and borderline conditions as reportable-by-agreement. Codes in the 20 range are for in situ only tumors. There is only one code, 20, for when there are at least two tumors and they are both in situ. Remember, you would have already gone through the MPH rules and the instructions said these were a single primary. For example, a cystoscopy report documents multiple bladder tumors. Pathology: Flat transitional cell carcinoma of bladder.

19 Slide 19 Code Code Text Description 30 In situ and invasive 31 Polyp and adenocarcinoma 32 FAP with carcinoma 40 Multiple invasive 80 Unk in situ or invasive One or more in situ tumor(s) AND one or more invasive tumors in the same organ/primary site One or more polyps with either In situ carcinoma or Invasive carcinoma AND one or more frank adenocarcinoma(s) in the same segment of colon, rectosigmoid, and/or rectum Familial polyposis (FAP) AND carcinoma (in situ or invasive) is present in at least one of the polyps At least two invasive tumors in the same organ Multiple tumors present in the same organ/primary site, unknown if in situ or invasive 88 NA Information on multiple tumors not collected/not applicable for this site 99 Unk Unknown 19 Codes in the 30 range are for in situ and invasive tumors. One tumor is invasive and one tumor in in situ. There are two special codes that apply to polyps in the colon and rectum. Use code 31 if there is a polyp and a frank adenocarcinoma abstracted as a single primary. Use code 32 if there is FAP with carcinoma in at least one polyp. Codes in the 40 range are for invasive only tumors. There is only one code, 40, for there is more than one tumor and they are all invasive.

20 Slide 20 Case Scenarios The next three slides include audio narrations. Each slide runs for approximately 3 minutes. Before you advance the presentation to the next slide, check to make sure your speakers or headphones are connected and adjusted to an appropriate volume. If you are not able to listen to the narration, complete instructors notes are provided with the slide. At this time, we are going to go through 3 case scenarios together. The case scenarios are narrated. If you do not have the ability to listen to the narration, complete speakers notes have been provided as well.

21 Slide 21 Case Scenario 1 January 4, Bladder cystectomy, final diagnosis: A. Poorly differentiated transitional cell carcinoma of the bladder trigone, 3.2cm, extending through muscular wall, margins free of tumor. B. Two separate, 1.0cm moderately differentiated papillary transitional cell carcinomas of the bladder within the dome of the bladder. Data Item Answer Rationale Ambiguous Terminology Date of Conclusive Terminology Multiplicity Counter Date of Multiple Tumors Type of Multiple Tumors Conclusive dx w/in 60 days of original dx N/A Case accessioned based on conclusive dx Three tumors present Multiple tumors at orig dx, abstracted as single primary Multiple invasive tumors 21 In this case, there are 3 tumors in the bladder, one in the trigone and two in the dome. If you were to take this case through the multiple primary rules, you would see this is one primary with multiple tumors. The first data item we are going to determine is ambiguous terminology. What we are looking for is was the case abstracted based on the use of ambiguous terminology. The list of ambiguous terms can be found on page 337. We looking for words such as apparently, consistent with, probable, etc. In this case, there was no use of such words. It just states straight out transitional cell carcioma and papillary transitional cell carcinoma. It doesn t say probably transitional carcinoma or anything like that. So, this case was abstracted based on the use of a conclusive diagnosis. So, we will assign code 0 for the ambiguous terminology data item. The next data item is the date of the conclusive diagnosis (if there was one) IF the case was originally abstracted using ambiguous terminology. Since the original diagnosis statement used conclusive terminology, this date is not applicable. So, we should record 8 s for the date. Multiplicity counter: Use to count the number of tumors reported as a single primary (not metastatic lesions). There were three primary tumors present in the bladder at the time of diagnosis. The MP rules told us this is a single primary. So, we will record 03 in this data item. Date of multiple tumors: And, now we need to record the date the multiple tumors were diagnosed. Using the only information we have in the case scenario, this was determined on January 4, So, we will record And the last data item is the type of multiple tumors: What we are looking for is was one invasive and the other in situ, or were all in situ or all invasive. In this example, all three tumors were invasive. So, the appropriate code is 40. There were two or more invasive tumors in the same organ.

22 Slide 22 Case Scenario 2 October 16, 2007 Renal Ultrasound Assessment: Probably renal cell carcinoma October 17, 2007 R nephrectomy Final diagnosis: Adenocarcinoma, probably clear cell type of renal cell carcinoma. Data Item Answer Rationale Conclusive dx w/in 60 days Ambiguous Terminology 0 of original dx N/A Case accessioned Date of Conclusive Terminology based on conclusive dx Multiplicity Counter Date of Multiple Tumors Type of Multiple Tumors One tumor only Single tumor Single tumor 00 Used to qualify the type of adenocarcinoma, not whether or not the case should be accessioned. 22 In this case, there was 1 tumors in the right kidney. There was an ultrasound that stated probably renal cell carcinoma on 10/16/07. Then, the next day, on resection, the final diagnosis was adenocarcinoma probably clear cell type of renal cell carcinoma. The first thing I want to point out is the use of the phrase probably clear cell type is used to qualify the type adenocarcinoma. There is a definite statement of adenocarcinoma. There is no ambiguous terminology used to describe the fact that the patient does have cancer. So, we are not going to consider this as an ambiguous diagnosis. So, with that said. The first data item we are going to determine is ambiguous terminology. They did use probably renal cell on the ultrasound. However, the rules tell us there is a two month time frame in which there can be a conclusive diagnosis. And, there was. It was only the next day. So, in this case there was a conclusive diagnosis within two months of the original diagnosis. So, we will assign code 0 for the ambiguous terminology data item. Since the case was originally abstracted using conclusive terminology, this date is not applicable. So, we should record 8 s for the date. Multiplicity counter: There was one primary tumor present at the time of diagnosis. So, we will record 01 in this data item. Date of multiple tumors: And, since this case doesn t have multiple tumors, the correct code for the date of multiple tumors data item is going to be 0 s to indicate that there was only one tumor. And, again, since this case does not have multiple tumors, the correct code is 00 to indicate that it was a single tumor only. So, the take home message with this case is not to just go scanning through the chart looking for any of the ambiguous terms listed on page 337. It has to be referring to the actual diagnosis.

23 Slide 23 Case Scenario 3 June 2, 2007 Prostate biopsy Assessment: Focal atypical small glands suspicious for minimal prostatic adenocarcinoma associated with high grade PIN. October 14, 2007 Prostatectomy Final diagnosis: Adenocarcinoma, well differentiated. Data Item Ambiguous Terminology Date of Conclusive Terminology Multiplicity Counter Date of Multiple Tumors Type of Multiple Tumors Codes when abstracted Go back and change the code Final codes And, we will do one more case together. In this case, there was a biopsy on June 2 that was suspicious for adenocarcinoma. So, there s a flag there, suspicious for adenocarcinoma. Then, 4 months later (there s another clue, it was more than 60 days later), a prostatectomy was done. The final diagnosis from that procedure was just straight out adenocarcinoma. The first data item we are going to determine is ambiguous terminology. This case was originally diagnosed in June and it did use ambiguous terminology suspicious for adenocarcinoma. So, when this case was originally accessioned, it would have been based on the ambiguous terminology. (in blue, column 2). The ambiguous terminology field would have been 1 for based on ambiguous terminology only and so on. Now, time goes on and the patient comes in for treatment and there is more information to add to your abstract. At this point in time, ambiguous terminology is not used. It is a conclusive diagnosis of adenocarcinoma. Now, this is probably the most cumbersome part of these data items. If you had already abstracted the case into your registry, you would have to remember to go back and update the codes based on the fact that there is now a conclusive diagnosis. Because it was more than 60 days later, we have to use a code of 2. And, the date the conclusive diagnosis was made was on , so we will record that in the date field. The rest of the date items will remain the same. Multiplicity counter: There was one primary tumor present at the time of diagnosis. So, we will record 01 in this data item. Date of multiple tumors: And, since this case doesn t have multiple tumors, the correct code for the date of multiple tumors data item is going to be 0 s to indicate that there was only one tumor. And, again, since this case does not have multiple tumors, the correct code is 00 to indicate that it was a single tumor only.

24 So, you may want to make a note somewhere that you need to remember to change these data items if, at a later time, more than 60 days later, there is a conclusive diagnosis. Slide 24 This concludes this presentation. Please return to the course content. This concludes this presentation. Later in this lesson, you will have an opportunity to work on additional practice cases. Please return to the course to continue this lesson.

ICD-O CODING Third Edition

ICD-O CODING Third Edition Slide 1 ICD-O CODING Third Edition PART I An introduction to the ICD-O-3 Coding Manual This is part 1 of a 2-part slide presentation. Use the navigation buttons below this panel to advance the slides.

More information

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #

DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC # DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases

More information

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific

More information

CASEFINDING. KCR Abstractor s Training

CASEFINDING. KCR Abstractor s Training CASEFINDING KCR Abstractor s Training 1 Introduction Casefinding Definition Purpose Methods Sources vs Resources Reportable Cancer Conditions Non-Reportable Conditions Ambiguous Terminology 2 https://www.google.com/search?q=puzzle+pieces&client=firefox-a&hs=mdc&rls=org.mozilla

More information

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) = Follow-up, Data Quality and Utilization Lesson 8 Page 5: Correcting the Edits Report Instructions: Use the spaces provided to fix the edit by providing the valid value for the incorrect data item. This

More information

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR Outcomes Watching It Grow GATRA Annual Conference 2016 Lisa Connor, CTR The abstract begins after case finding The abstract is in progress The abstract is complete The abstract is revisited and nurtured

More information

There is no longer a non-reportable list of terms. If a term you are looking for does not appear on this list, the case is NOT reportable.

There is no longer a non-reportable list of terms. If a term you are looking for does not appear on this list, the case is NOT reportable. Michigan Cancer Surveillance Program October 2006 Update Michigan Cancer Surveillance Program (MCSP) Cancer Reporting Manual ~ Coming soon! An updated copy of the MCSP Cancer Reporting Manual will be available

More information

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:

More information

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in

More information

Who What When Where Why. Case Finding 5 W s. NAACCR Webinar Series. Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC

Who What When Where Why. Case Finding 5 W s. NAACCR Webinar Series. Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC Who What When Where Why Case Finding 5 W s NAACCR 2010-2011 Webinar Series Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC Agenda Case Finding Purpose Reportable lists Benign intracranial

More information

A patient with recurrent bladder cancer presents with the following history:

A patient with recurrent bladder cancer presents with the following history: MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from

More information

Requirements for Abstracted Text

Requirements for Abstracted Text Slide 1 Requirements for Abstracted Text Principles of Abstracting Lesson 3: Purpose of Text Slide 2 Available Text Fields Place of Diagnosis Immunotherapy Chemotherapy Hormone Therapy Other Therapy Radiation

More information

NAACCR Grade 2018 Q & A

NAACCR Grade 2018 Q & A NAACCR Grade 2018 Q & A GRADE RULES Q: Can you assign a pathologic grade if bx of highest T AND bx of highest N, where case meets criteria for pathologic staging? A:The grade rules indicate for a pathological

More information

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done. Q&A Breast Webinar Q: One of my investigators is interested in knowing when Oncotype DX data collection was implemented. That data is collected in SSFs 22 and 23. I remember that the SSFs for breast were

More information

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data

More information

COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING

COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING COLON AND RECTUM SOLID TUMOR RULES ABSTRACTORS TRAINING COLON AND RECTUM SOLID TUMOR RULES Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent Terms Terms that are NOT Equivalent

More information

This section allows identifying the facility, this information is important for data quality follow up. Source of Standard. Source of Standard

This section allows identifying the facility, this information is important for data quality follow up. Source of Standard. Source of Standard Data Dictionary Case Administration This section allows identifying the facility, this information is important for data quality follow up Facility Name This identifier is needed to evaluate This data

More information

2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING

2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING 2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Eight Groups are Revised for 2018 Head & Neck Colon (includes rectosigmoid and rectum for cases diagnosed 1/1/2018 forward) Lung (2018 Draft not yet

More information

FINALIZED SEER SINQ S MAY 2012

FINALIZED SEER SINQ S MAY 2012 FINALIZED SEER SINQ S MAY 2012 : 20120039 Primary site/heme & Lymphoid Neoplasms: What site do I code this to and what rule applies? How did you arrive at this? Please advise. See discussion. Patient with

More information

Mississippi Cancer Registry Reporting Manual Revised 2016

Mississippi Cancer Registry Reporting Manual Revised 2016 Mississippi Cancer Registry Reporting Manual Revised 2016 TABLE OF CONTENTS Program Overview... 2 Confidentiality... 2 General Instructions... 3 Quality Control... 4 Reporting Procedures..5 Coding Rules

More information

Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?

Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term surface on the path report? Q&A Session for Collecting Cancer Data: Ovary Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report? A: We reviewed both the

More information

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).

Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009

More information

Collaborative Staging

Collaborative Staging Slide 1 Collaborative Staging Site-Specific Instructions Prostate 1 In this presentation, we are going to take a closer look at the collaborative staging data items for the prostate primary site. Because

More information

Quiz. b. 4 High grade c. 9 Unknown

Quiz. b. 4 High grade c. 9 Unknown Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm

More information

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume

More information

Evaluation of Abstracting: Cancers Diagnosed in MCSS Quality Control Report 2005:2. Elaine N. Collins, M.A., R.H.I.A., C.T.R

Evaluation of Abstracting: Cancers Diagnosed in MCSS Quality Control Report 2005:2. Elaine N. Collins, M.A., R.H.I.A., C.T.R Evaluation of Abstracting: Cancers Diagnosed in 2001 MCSS Quality Control Report 2005:2 Elaine N. Collins, M.A., R.H.I.A., C.T.R Jane E. Braun, M.S., C.T.R John Soler, M.P.H September 2005 Minnesota Department

More information

2018 New Grade Coding Rules It s a Good Thing!

2018 New Grade Coding Rules It s a Good Thing! 2018 New Grade Coding Rules It s a Good Thing! Presented by Donna M. Hansen, CTR California Cancer Registry NAACCR Webinar May 1, 2018 & May 2, 2018 1 Acknowledgement Special Thanks To: Jennifer Ruhl,

More information

Histology Coding ANSWERS

Histology Coding ANSWERS Histology Coding ANSWERS 1.) Biopsy of a right thyroid nodule reveals papillary carcinoma. What is the ICD-O-3 code? a. 8050/3 - Papillary carcinoma b. 8260/3 - Papillary adenocarcinoma Rationale/comment:

More information

Colon and Rectum: 2018 Solid Tumor Rules

Colon and Rectum: 2018 Solid Tumor Rules 2018 SEER Solid Tumor Manual 2018 KCR SPRING TRAINING Colon and Rectum: 2018 Solid Tumor Rules 1 Colon and Rectum Solid Tumor Rules Separate sections for: Introduction Changes from 2007 MP/H rules Equivalent

More information

Seventh Edition Staging 2017 Breast

Seventh Edition Staging 2017 Breast Seventh Edition Staging 2017 Breast Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written

More information

Patient Identification Quiz

Patient Identification Quiz Patient Identification Quiz 1. A patient presents to your facility for the first time on 1/1/2009. At that time he has a history of lymphoma (9590/3), melanoma (8720/3) and meningioma (9530/0). These three

More information

I.2 CNExT This section was software specific and deleted in 2008.

I.2 CNExT This section was software specific and deleted in 2008. CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION

More information

Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012

Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012 Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012 Q: Will sticky notes be transferrable from the previous electronic version of CS to the updated version? A: It is our

More information

Tumor Comparison. NAACCR Death Clearance Manual Update. Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013

Tumor Comparison. NAACCR Death Clearance Manual Update. Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013 Tumor Comparison NAACCR Death Clearance Manual Update Bobbi Jo Matt, BS RHIT CTR NAACCR 2013 Conference, Austin, TX June 12, 2013 Tumor Comparison The process of comparing the registry s tumors to the

More information

Kidney, Bladder and Prostate Neoplasia. David Bingham MD

Kidney, Bladder and Prostate Neoplasia. David Bingham MD Kidney, Bladder and Prostate Neoplasia David Bingham MD typical malignant cytology of bladder washings 1 benign 2 malignant typical malignant cytology of bladder washings b Bladder tumor Non invasive papillary

More information

Kidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification

Kidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification Kidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification A1: Yes. See below. I don't think it will have a start date. Clarification

More information

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein

INTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic

More information

2007 Multiple Primary and

2007 Multiple Primary and 2007 Multiple Primary and Histology Coding Rules Beyond the Basics Florida Cancer Data System Annual Conference Tampa, FL July 26,2007 Steven Peace, CTR Westat Carol Johnson, CTR NCI SEER Peggy Adamo,

More information

Outline (1) Outline (2) Concepts in Prostate Pathology. Peculiarities of Prostate Cancer. Peculiarities of Prostate Cancer

Outline (1) Outline (2) Concepts in Prostate Pathology. Peculiarities of Prostate Cancer. Peculiarities of Prostate Cancer Concepts in Prostate Pathology Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Outline (1) Peculiarities of prostate cancer Peculiarities of prostate needle biopsy Needle bx vs. TURP Prostate

More information

NAACCR Webinar Series 1

NAACCR Webinar Series 1 NAACCR 2009 2010 Webinar Series Collecting Cancer Data: Kidney 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes 3 NAACCR 2009 2010 Webinar

More information

SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING

SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING OVERVIEW What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets Site Specific Data Items (SSDI) SEER Summary

More information

Definition of Synoptic Reporting

Definition of Synoptic Reporting Definition of Synoptic Reporting The CAP has developed this list of specific features that define synoptic reporting formatting: 1. All required cancer data from an applicable cancer protocol that are

More information

Kentucky Cancer Registry Spring Training 2017

Kentucky Cancer Registry Spring Training 2017 Kentucky Cancer Registry Spring Training 2017 What we will cover Coding instructions for grade Case examples addressing some areas of confusion for grade New grade data items coming in 2018 TNM Where to

More information

Change Log V1.3- v1.4

Change Log V1.3- v1.4 Change Log V1.3- v1.4 This document shows the changes that were made to the SSDI manual and the Grade manual for the SEER*RSA version 1.4 release on (Date TBD). SSDI Manual Section: General Instructions

More information

Coding Pitfalls 9/1/2011. Coding Pitfalls Questions. Fabulous Prizes!!! September 1, NAACCR Webinar Series 1

Coding Pitfalls 9/1/2011. Coding Pitfalls Questions. Fabulous Prizes!!! September 1, NAACCR Webinar Series 1 Coding Pitfalls 2010 2011 September 1, 2011 NAACCR 2010 2011 Webinar Series Questions Please submit questions about today s presentation through the Q&A (?) panel Fabulous Prizes!!! For the best question

More information

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management. Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician

More information

Multiple Primary and Histology Site Specific Coding Rules BREAST. FLORIDA CANCER DATA SYSTEM MPH Breast Site Specific Coding Rules

Multiple Primary and Histology Site Specific Coding Rules BREAST. FLORIDA CANCER DATA SYSTEM MPH Breast Site Specific Coding Rules Multiple Primary and Histology Site Specific Coding Rules BREAST 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology

More information

We re on the Web! Visit us at VOLUME 19 ISSUE 1. January 2015

We re on the Web! Visit us at   VOLUME 19 ISSUE 1. January 2015 VOLUME 19 ISSUE 1 January 2015 We re on the Web! Visit us at www.kumc.edu/kcr January is National Cervical Cancer Screening Month. Cervical cancer begins in the lining of the cervix (organ connecting the

More information

Prostate Overview Quiz

Prostate Overview Quiz Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the

More information

CS Evaluation Fields. Outline of Presentation. Purpose of Evaluation Field. CSv2 Title of Presentation Jan 2011 Lecture Version: 1.

CS Evaluation Fields. Outline of Presentation. Purpose of Evaluation Field. CSv2 Title of Presentation Jan 2011 Lecture Version: 1. CS Evaluation Fields Education and Training Team Collaborative Stage Data Collection System Version 02.03.02 (Effective date: 1/1/2011) Outline of Presentation Purpose AJCC TNM Classification Eval data

More information

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014 Q: If polycythemia ruba vera (PRV) or essential thrombocythemia (ET) is diagnosed by peripheral smear,

More information

CODING TUMOUR MORPHOLOGY. Otto Visser

CODING TUMOUR MORPHOLOGY. Otto Visser CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show

More information

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT)

Bladder Case 1 SURGICAL PATHOLOGY REPORT. Procedure: Cystoscopy, transurethral resection of bladder tumor (TURBT) Bladder Case 1 February 17, 2007 Specimen (s) received: Bladder Tumor Pre-operative Diagnosis: Bladder Cancer Post operative Diagnosis: Bladder Cancer Procedure: Cystoscopy, transurethral resection of

More information

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR MCR: MANAGEMENT OF 2018 CHANGES By: Maricarmen Traverso-Ortiz MPH, CGG, CTR LEARNING OBJECTIVES Discuss a summary of the new changes for 2018 Overview of how the Maryland Cancer Registry is managing and

More information

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ Primary Site (291) = C711 Date of Diagnosis (283) =

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ Primary Site (291) = C711 Date of Diagnosis (283) = Follow-up, Data Quality and Utilization Lesson 8 Page 5: Correcting the Edits Report Instructions: Use the spaces provided to fix the edit by providing the valid value for the incorrect data item. This

More information

SEER Summary Stage Still Here!

SEER Summary Stage Still Here! SEER Summary Stage Still Here! CCRA NORTHERN REGION STAGING SYMPOSIUM SEPTEMBER 20, 2017 SEER Summary Stage Timeframe: includes all information available through completion of surgery(ies) in the first

More information

A CENTRAL REGISTRY RELIABILITY STUDY

A CENTRAL REGISTRY RELIABILITY STUDY A CENTRAL REGISTRY RELIABILITY STUDY Visual Editor TNM & Summary Stage Staging Skill Assessment Donna M. Hansen, CTR Auditor & Education Training Coordinator California Cancer Registry NAACCR June 16,

More information

Interactive Discussion of Part I CS Coding Instructions: Working the Cases

Interactive Discussion of Part I CS Coding Instructions: Working the Cases Interactive Discussion of Part I CS Coding Instructions: Working the Cases April Fritz, RHIT, CTR Donna M. Gress, RHIT, CTR Jennifer Ruhl, RHIT, CCS, CTR This presentation was supported by the Cooperative

More information

Urology An introduction to cut up DR J R GOEPEL

Urology An introduction to cut up DR J R GOEPEL Urology An introduction to cut up DR J R GOEPEL Overview Principles Individual organs Small pieces Partial resections Whole organs Data recording and data sets Principles You are working for the patient

More information

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement

More information

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement

More information

Thyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect

Thyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect Thyroid Pathology: It starts and ends with the gross Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1

Other Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1 MPH s 11/8/07 Other s 1 Table 2 Continued Use this two-page table to select combination histology codes. Compare the terms in the diagnosis to the terms in Columns 1 and 2. If the terms match, code the

More information

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report

More information

Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data,

Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data, Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data, 2004-2012 Jeanne Whitlock, MSLS, CTR Julie George, MS Ron Shore, MPH Fawn D. Vigneau, JD, MPH Metropolitan

More information

Introduction & Descriptors

Introduction & Descriptors AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving

More information

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving

More information

2015 Patient Outcomes Report

2015 Patient Outcomes Report 2015 Patient Outcomes Report Message from the Breast Leadership Team and Cancer Committee: On behalf of the Breast Leadership Team and Cancer Committee of The Hospitals, we are pleased to present to you

More information

Faster Cancer Treatment Indicators: Use cases

Faster Cancer Treatment Indicators: Use cases Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:

More information

Instructions for Coding Grade for 2014+

Instructions for Coding Grade for 2014+ Instructions for Coding for 2014+ GRADE, DIFFERENTIATION OR CELL INDICATOR Item Length: 1 NAACCR Item #: 440 NAACCR Name:, Differentiation for solid tumors (Codes 1, 2, 3, 4, 9) and Cell Indicator for

More information

7/29/ Grade Coding Instructions ICD-O-3 Updates. Outline. Introduction to Coding Grade for 2014+

7/29/ Grade Coding Instructions ICD-O-3 Updates. Outline. Introduction to Coding Grade for 2014+ 2014 Grade Coding Instructions ICD-O-3 Updates 1 I M P L E M E N T A T I O N T I M E L I N E ( S ) 2 0 1 4 F C D S D A M A P P E N D I X H A N D O U T S F C D S A N N U A L C O N F E R E N C E O R L A

More information

Major Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

Major Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging AJCC 8 th Edition Staging Major Rule Changes Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving patient

More information

Commission on Cancer Updates

Commission on Cancer Updates Commission on Cancer Updates OBJECTIVES PROVIDE CANCER REGISTRARS WITH INFORMATION ABOUT CURRENT COC 2018 CHANGES DISCUSS CHANGES RELATED TO CANCER REGISTRY DATA COLLECTION DISCUSS CHANGES RELATED TO CANCER

More information

Pathology Driving Decisions

Pathology Driving Decisions Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He

More information

WHI Extension Appendix A, Form Report of Cancer Outcome (Ver. 8.2) Page 1

WHI Extension Appendix A, Form Report of Cancer Outcome (Ver. 8.2) Page 1 WHI Extension Appendix A, Form 130 - Report of Cancer Outcome (Ver. 8.2) Page 1 FORM: 130 - REPORT OF CANCER OUTCOME Version: 8.2 October 30, 2008 Description: When used: Purpose: 4-page form filled out

More information

Combatting Pancreatic Cancer: Keys to Early Recognition and Diagnosis

Combatting Pancreatic Cancer: Keys to Early Recognition and Diagnosis Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/combatting-pancreatic-cancer-keys-earlyrecognition-and-diagnosis/7286/

More information

REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after

REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable

More information

Case Scenario 1: Breast

Case Scenario 1: Breast Case Scenario 1: Breast A 63 year old white female presents with a large mass in her left breast. 4/15/13 Mammogram/US: 1. Left breast mammographic and sonographic at 3:00 measuring 7.1 cm highly suggestive

More information

FINALIZED SEER SINQ S NOVEMBER 2011

FINALIZED SEER SINQ S NOVEMBER 2011 : 20110133 Multiple primaries/heme & Lymphoid Neoplasms: A patient was diagnosed 7/31/08 with DLBCL (9680/3) (biopsy left supraclav. node), stage IIIB. Treated with chemo. 10/14/10 biopsy right supraclav.

More information

The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light.

The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light. Acknowledgment The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light. Special appreciation goes to: Prof Amal Samy

More information

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving

More information

Purpose. Encourage standard exchange of data between two key public health partners

Purpose. Encourage standard exchange of data between two key public health partners Reporting Pathology Protocols for Colorectal Cancer 2005 NAACCR Conference: June 9, 2005 Ken Gerlach: CDC-NPCR Bette Smith: Ohio Cancer Registry Kathleen Davidson-Allen: PHI/California Cancer Registry

More information

OSCaR UPDATE. Manager s Update Donald Shipley, MS. Oregon State Cancer Registry

OSCaR UPDATE. Manager s Update Donald Shipley, MS. Oregon State Cancer Registry Oregon State Cancer Registry OSCaR UPDATE VOLUME 8, QUARTER 4 W INTER 2008 Manager s Update Donald Shipley, MS Since the Fall issue of OSCaR Update, the registry staff has completed several significant

More information

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase

PSA. HMCK, p63, Racemase. HMCK, p63, Racemase Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml

More information

Neoplasms of the Prostate and Bladder

Neoplasms of the Prostate and Bladder Neoplasms of the Prostate and Bladder 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 CDC & Florida DOH Attribution

More information

CASEFINDING. Debra W. Christie, MBA, RHIA, CTR, CCRP Director, Cancer Research & Data Center University of Mississippi Medical Center

CASEFINDING. Debra W. Christie, MBA, RHIA, CTR, CCRP Director, Cancer Research & Data Center University of Mississippi Medical Center CASEFINDING Debra W. Christie, MBA, RHIA, CTR, CCRP Director, Cancer Research & Data Center University of Mississippi Medical Center Casefinding Systematic process to identify all cases eligible to be

More information

Obtaining the diagnosis:

Obtaining the diagnosis: CANCER SURGERY Obtaining the diagnosis: Most cancers are first biopsied in order to determine tumor type. Incisional biopsies extract small portions of tumor for microscopic examination. Excisional biopsies

More information

Pancreatic Cancer: Associated Signs, Symptoms, Risk Factors and Treatment Approaches

Pancreatic Cancer: Associated Signs, Symptoms, Risk Factors and Treatment Approaches Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/pancreatic-cancerassociated-signs-symptoms-and-risk-factors-and-treatment-approaches/9552/

More information

Cancer Program Report 2014

Cancer Program Report 2014 Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167

More information

MEDitorial March Bladder Cancer

MEDitorial March Bladder Cancer MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting

More information

WHI Extension Section 8 Outcomes Page 8-85

WHI Extension Section 8 Outcomes Page 8-85 WHI Extension Section 8 Outcomes Page 8-85 8.11 For m 130 Repor t of Cancer Outcome The CCC Outcomes staff places the participant s barcode ID label in the space provided at the top of the form and routes

More information

Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to fina

Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to fina Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to finally be able to put these genomics related data items

More information

Metachronic solitary breast metastasis from renal cell carcinoma: case report

Metachronic solitary breast metastasis from renal cell carcinoma: case report Metachronic solitary breast metastasis from renal cell carcinoma: case report Abstract We describe the case of a patient with solitary and metachronic breast metastasis, 3 years after nephrectomy for renal

More information

FINALIZED SEER SINQ QUESTIONS April July, 2017

FINALIZED SEER SINQ QUESTIONS April July, 2017 20170040 Source 1: 2016 SEER Manual pgs: 91 Source 2: 2007 MP/H Rules Notes: Lung MP/H Rules/Histology--Lung: What is the histology code for lung cancer case identified pathologically from a metastatic

More information

Bladder Cancer Knowing the Risks and Warning Signs. Part II: Warning Signs

Bladder Cancer Knowing the Risks and Warning Signs. Part II: Warning Signs Bladder Cancer Knowing the Risks and Warning Signs Part II: Warning Signs May 8, 2018 Presented by: is the Director of Urologic Oncology at MedStar Washington Hospital Center and an Assistant Professor

More information

BREAST PATHOLOGY. Fibrocystic Changes

BREAST PATHOLOGY. Fibrocystic Changes BREAST PATHOLOGY Lesions of the breast are very common, and they present as palpable, sometimes painful, nodules or masses. Most of these lesions are benign. Breast cancer is the 2 nd most common cause

More information

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction

More information

Colorectal Cancer Screening

Colorectal Cancer Screening Tool 2.1 Cancer Screening Basic Fact Sheet Are You at High Risk? Your risk for colorectal cancer may be higher than average if: stomach You or a close relative have had colorectal polyps or colorectal

More information

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017 Completing the Puzzle AJCC TNM Staging Breast Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017 OBJECTIVES Understanding of Breast TNM staging Identify clinical

More information